TSX:GUD - Post Discussion
Post by
GoldenInvestor on Apr 18, 2024 5:52pm
GUD Motley fool article April 16, GUD shares +40%
https://www.fool.ca/2024/04/16/tsx-healthcare-in-april-2024-the-best-stocks-to-buy-right-now/ *****
Positioned for future success
Knight Therapeutics trades slightly higher than WELL ($5.42 per share), but the potential price appreciation is equally enticing. Based on market analysts’ “strong buy” recommendations, GUD could rise by as much as 40% to $7.60 in one year.
This $582.74 million specialty pharmaceutical company focused on acquiring, in-licensing, out-licensing, marketing, and commercializing innovative prescription pharmaceuticals. Knight’s primary goal is to bring branded generic products to Canada and Latin America. As of year-end 2023, it has a robust pipeline of 17 products in 11 countries.
In 2023, revenues increased 12% to $328.2 million versus 2022, while net loss thinned 44% year over year to $16.8 million. Management said Knight Therapeutics is well-positioned for future success due to its unique and profitable platform. The 17 products in the pipeline should be launch-ready by 2028 and deliver over $120 million in peak revenues.
Be the first to comment on this post